DJIA 16,607.10 -47.67 -0.29%
NASDAQ 4,813.51 0.80 0.02%
S&P 500 1,984.85 -2.81 -0.14%
market minute promo

Medivation, Inc. (NASDAQ: MDVN)



company name or ticker

Medivation to Gain Global Rights to BioMarin's Talazoparib

Biomarin Goes For Pragmatism As The Markets Dip

Benzinga's M&A Chatter for Monday August 24, 2015

Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talaz

Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib, a Potent PARP Inhibitor, From BioMarin

3 Biotech Stocks We Love

Our analysts can't help but fall in love with these three biotech stocks.

Patent Claims To Xtandi Seem Weak

Medivation Tops Q2 Earnings & Ups View, Xtandi Impresses - Analyst Blog

Medivation Tops Q2 Earnings & Ups View, Xtandi Impresses - Analyst Blog

Medivation (MDVN) Earnings Report: Q2 2015 Conference Call Transcript

Medivation (MDVN) David T. Hung on Q2 2015 Results - Earnings Call Transcript

Medivation (MDVN) Q2 2015 Results - Earnings Call Webcast

See More Articles...